BDX Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

149.225

Open

148.260

VWAP

147.66

Vol

3.73M

Mkt Cap

40.54B

Low

146.641

Amount

550.54M

EV/EBITDA(TTM)

9.61

Total Shares

275.54M

EV

57.36B

EV/OCF(TTM)

14.70

P/S(TTM)

1.91

Becton, Dickinson and Company is a global medical technology company. The Company is engaged in the development, manufacture and sale of a broad range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, and more. It operates through five segments: BD Medical Essentials, BD Connected Care, BD BioPharma Systems, BD Interventional, and BD Life Sciences. BD Medical Essentials segment includes medication delivery solutions and specimen management. BD Connected Care segment includes medication management solutions and advanced patient monitoring. BD Interventional segment includes urology and critical care, peripheral intervention and surgery. Its Life Sciences segment includes diagnostic solutions and biosciences.

Show More

Events Timeline

(ET)

2026-05-07

16:30:00

Major Averages Close Lower, McDonald's Reports Growth

2026-05-07

12:00:00

Major Averages Little Changed as Oil Prices Decline Reflect Optimism

2026-05-07

09:00:00

Futures Rise on Declining Oil Prices

2026-05-07

07:00:00

Becton Dickinson Appoints Vitor Roque as CFO

2026-05-07

06:50:00

Company Raises FY26 Revenue Outlook to Low Single-Digits

2026-05-07

06:50:00

BD Reports Q2 Revenue of $4.71B, Exceeds Expectations

2026-05-06 (ET)

2026-05-06

15:00:00

McDonald's and Others Earnings Consensus Before Tomorrow's Open

2026-05-05 (ET)

2026-05-05

09:20:00

Becton Dickinson Partners with Wellstar for Medication Safety

News

Fool

Analysis of Blue Chip Stock Investment Strategies

NASDAQ.COM

05-29NASDAQ.COM

Microsoft Shares Undervalued; Blue Chip Investment Opportunities

PRnewswire

05-21PRnewswire

BD Launches New Laser System to Enhance Urology Efficiency

PRnewswire

05-18PRnewswire

BD Appoints New Executive Vice President

CNBC

Roundhill Memory ETF DRAM Attracts Over $5 Billion in Investments

Newsfilter

05-07Newsfilter

Becton Dickinson Exceeds Q2 Estimates with $4.71B Revenue

11 Analyst Rating

Wall Street analysts forecast BDX stock price to rise

5 Buy

6 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

157.00

Averages

192.64

High

232.00

Current: 0.000

Low

157.00

Averages

192.64

High

232.00

Barclays

NULL -> Overweight

maintain

$202 -> $204

AI Analysis

2026-05-11

Reason

Barclays

Price Target

$202 -> $204

AI Analysis

2026-05-11

maintain

NULL -> Overweight

Reason

Barclays raised the firm's price target on Becton Dickinson to $204 from $202 and keeps an Overweight rating on the shares post the fiscal Q2 report. Becton delivered solid operational growth and upside to consensus estimates, the analyst tells investors in a research note. The firm views the company as well positioned in the current macro environment.

Evercore ISI

Outperform

initiated

$180

2026-05-04

Reason

Evercore ISI

Price Target

$180

2026-05-04

initiated

Outperform

Reason

Evercore ISI resumed coverage of Becton Dickinson with an Outperform rating and $180 price target. Becton Dickinson is in a transition year with the biosciences and diagnostics separation and a series of transitory headwinds \"masking a more stable underlying growth profile,\" the analyst tells investors.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for BDX

Unlock Now

Valuation Metrics

The current forward P/E ratio for Becton Dickinson and Co (BDX.N) is 11.74, compared to its 5-year average forward P/E of 17.91. For a more detailed relative valuation and DCF analysis to assess Becton Dickinson and Co's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

5Y Average PE

17.91

Current PE

11.74

Overvalued PE

21.48

Undervalued PE

14.34

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

5Y Average EV/EBITDA

14.58

Current EV/EBITDA

10.88

Overvalued EV/EBITDA

16.74

Undervalued EV/EBITDA

12.42

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

5Y Average PS

3.29

Current PS

2.06

Overvalued PS

3.83

Undervalued PS

2.74

Financials

AI Analysis

Annual

Quarterly

Whales Holding BDX

Mubadala Investment Company PJSC

Cacti Asset Management, LLC

Kovitz Investment Group Partners, LLC

American Century Investment Management

Deroy & Devereaux Private Investment Counsel, Inc.

ClearBridge Investments, LLC

Trading Trends

People Also Watch

Frequently Asked Questions

What is Becton Dickinson and Co (BDX) stock price today?

The current price of BDX is 147.12 USD — it has decreased -0.87

What is Becton Dickinson and Co (BDX)'s business?

Becton, Dickinson and Company is a global medical technology company. The Company is engaged in the development, manufacture and sale of a broad range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, and more. It operates through five segments: BD Medical Essentials, BD Connected Care, BD BioPharma Systems, BD Interventional, and BD Life Sciences. BD Medical Essentials segment includes medication delivery solutions and specimen management. BD Connected Care segment includes medication management solutions and advanced patient monitoring. BD Interventional segment includes urology and critical care, peripheral intervention and surgery. Its Life Sciences segment includes diagnostic solutions and biosciences.

What is the price predicton of BDX Stock?

Wall Street analysts forecast BDX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BDX is192.64 USD with a low forecast of 157.00 USD and a high forecast of 232.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Becton Dickinson and Co (BDX)'s revenue for the last quarter?

Becton Dickinson and Co revenue for the last quarter amounts to 4.71B USD, increased 5.22

What is Becton Dickinson and Co (BDX)'s earnings per share (EPS) for the last quarter?

Becton Dickinson and Co. EPS for the last quarter amounts to -1.11 USD, decreased -203.74

How many employees does Becton Dickinson and Co (BDX). have?

Becton Dickinson and Co (BDX) has 72000 emplpoyees as of May 31 2026.

What is Becton Dickinson and Co (BDX) market cap?

Today BDX has the market capitalization of 40.54B USD.